DaviesCBriggsALorgellyPGarellickGMalchauH. The “hazards” of extrapolating survival curves. Med Decis Making. 2013;33:369–80.
2.
LatimerNR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. doi:10.1177/0272989X12472398.
GuyotPWeltonNJOuwensMJNMAdesAE. Survival time outcomes in randomised controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. Value Health. 2011;14(5):640–6.
5.
RoystonPParmarMKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med. 2002, 21:2175–97.
6.
BradburnMJClarkTGLoveSBAltmanDG. Survival analysis, part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer. 2001;89(4):605.
7.
JansenJP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.
JacksonCThompsonSSharplesLD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Series A. 2009;172:383–404.
